Navigation Links
Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0%

DUBLIN, July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling. Other companies that have submitted NDAs referencing AndroGel® 1.0% have failed to achieve the AB rating.

Androgel® 1.0% (testosterone gel 1.0%) is indicated to treat adult males who have low or no testosterone. Annual sales were greater than $500 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "We are very pleased to receive an AB rating for our testosterone 1.0% product. It occurred as a result of a strong effort by our research and development team, which worked alongside the FDA. We sincerely commend the FDA team on its actions and appreciate their hard work to bring this matter to conclusion. This highlights our commitment to bringing new affordable products to the market."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products®" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Photo -

SOURCE Perrigo Company
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company plc To Host Investor Day And To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
3. Perrigo Confirms Filing For Generic Version Of Acanya
4. Perrigo Shareholders Approve Proposals Related To Perrigos Proposed Acquisition Of Elan
5. Perrigo Company Announces Tender Offer and Consent Solicitation for its 2.950% Notes due 2023
6. Perrigo Initiates Nationwide Voluntary Product Recall Of Acetaminophen Infant Suspension Liquid, 160 mg/5 mL, Due To A Potential Defect With The Co-Packaged Oral Syringe
7. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
8. Perrigo Company To Release First Quarter Fiscal Year 2014 Results On October 31, 2013
9. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
10. Perrigo Nutritionals Works with the American Academy of Pediatrics (AAP) on Infant Nutrition Educational Initiative
11. Perrigo Company Will Release Fourth Quarter And Fiscal Year 2013 Results On August 15, 2013
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... There is only one major question facing all law firms in ... question has not been an easy question to answer. Especially when the senior partners ... workforce don’t share the same discipline around working long hours. , In addition ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
Breaking Medicine News(10 mins):